Marcelo C Pasquini, MD | Medical College of Wisconsin

Marcelo C. Pasquini, MD

Professor

view physician profile

Locations

Froedtert Hospital
Cancer Center - Froedtert Hospital

Specialties

Medical Oncology

Languages

English, Spanish, Portuguese

Cancer Center - Froedtert Hospital

(414) 805-0505

Education

MD - Doctor of Medicine

Biography

Marcelo C. Pasquini, MD, MS, is a Professor of Medicine in the Division of Hematology and Oncology. He completed medical school at the State University of Londrina, Brazil; postgraduate training in Internal Medicine at the University of Miami/Jackson Memorial Hospital; Hematology and Oncology at the University of Utah; and Blood and Marrow Transplantation at the Medical College of Wisconsin. He received his Masters of Science degree in Epidemiology from the Medical College of Wisconsin. Dr. Pasquini also serves as Senior Scientific Director for Clinical Trials at the Center for International Blood and Marrow Transplant Research (CIBMTR) where he focuses on clinical research in the field of transplantation.

Research Interests

His medical practice is focused on hematologic malignancies, including multiple myeloma, acute myeloid leukemia, myelodysplasia and the use of blood and marrow transplantation for treatment of these diseases.

Prognostic impact of pre-transplant chromosomal aberrations in peripheral blood of patients undergoing unrelated donor hematopoietic cell transplant for acute myeloid leukemia.

(Wang Y, Zhou W, McReynolds LJ, Katki HA, Griffiths EA, Thota S, Machiela MJ, Yeager M, McCarthy P, Pasquini M, Wang J, Karaesmen E, Rizvi A, Preus L, Tang H, Wang Y, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Hahn TE, Sucheston-Campbell LE, Gadalla SM.) Sci Rep. 2021 Jul 22;11(1):15004 PMID: 34294836 PMCID: PMC8298542 SCOPUS ID: 2-s2.0-85111080464 07/24/2021
Phase II Trial of Costimulation Blockade With Abatacept for Prevention of Acute GVHD.

(Watkins B, Qayed M, McCracken C, Bratrude B, Betz K, Suessmuth Y, Yu A, Sinclair S, Furlan S, Bosinger S, Tkachev V, Rhodes J, Tumlin AG, Narayan A, Cribbin K, Gillespie S, Gooley TA, Pasquini MC, Hebert K, Kapoor U, Rogatko A, Tighiouart M, Kim S, Bresee C, Choi SW, Davis J, Duncan C, Giller R, Grimley M, Harris AC, Jacobsohn D, Lalefar N, Norkin M, Farhadfar N, Pulsipher MA, Shenoy S, Petrovic A, Schultz KR, Yanik GA, Waller EK, Levine JE, Ferrara JL, Blazar BR, Langston A, Horan JT, Kean LS.) J Clin Oncol. 2021 Jun 10;39(17):1865-1877 PMID: 33449816 PMCID: PMC8260909 SCOPUS ID: 2-s2.0-85107605861 01/16/2021
Blueprint for the discovery of biomarkers of toxicity and efficacy for CAR T cells and T-cell engagers.

(Paczesny S, Pasquini MC, Pavletic SZ, Agarwal A, Spellman S, Kean L, Bernatchez C, Gust J, Staedtke V, Perales MA.) Blood Adv. 2021 06 08;5(11):2519-2522 PMID: 34100901 PMCID: PMC8238483 SCOPUS ID: 2-s2.0-85108351661 06/09/2021
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

(Holstein SA, Bahlis N, Bergsagel PL, Bhutani M, Bolli N, Brownstein C, Demolis P, Foureau D, Gay F, Ghobrial IM, Gormley N, Hillengass J, Kaiser M, Maus MV, Melenhorst JJ, Merz M, Dwyer MO, Paiva B, Pasquini MC, Shah N, Wong SW, Usmani SZ, McCarthy PL.) Transplant Cell Ther. 2021 Jun 06 PMID: 34107340 06/10/2021
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.

(Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME.) Transplant Cell Ther. 2021 06;27(6):483.e1-483.e6 PMID: 33775615 PMCID: PMC8217373 SCOPUS ID: 2-s2.0-85106302930 03/30/2021
Beyond the storm - subacute toxicities and late effects in children receiving CAR T cells.

(Shalabi H, Gust J, Taraseviciute A, Wolters PL, Leahy AB, Sandi C, Laetsch TW, Wiener L, Gardner RA, Nussenblatt V, Hill JA, Curran KJ, Olson TS, Annesley C, Wang HW, Khan J, Pasquini MC, Duncan CN, Grupp SA, Pulsipher MA, Shah NN.) Nat Rev Clin Oncol. 2021 06;18(6):363-378 PMID: 33495553 PMCID: PMC8335746 SCOPUS ID: 2-s2.0-85099769741 01/27/2021
Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation.

(Farhadfar N, Dias A, Wang T, Fretham C, Chhabra S, Murthy HS, Broglie L, D'Souza A, Gadalla SM, Gale RP, Hashmi S, Al-Homsi AS, Hildebrandt GC, Hematti P, Rizzieri D, Chee L, Lazarus HM, Bredeson C, Jaimes EA, Beitinjaneh A, Bashey A, Prestidge T, Krem MM, Marks DI, Benoit S, Yared JA, Nishihori T, Olsson RF, Freytes CO, Stadtmauer E, Savani BN, Sorror ML, Ganguly S, Wingard JR, Pasquini M.) Transplant Cell Ther. 2021 05;27(5):410-422 PMID: 33775617 PMCID: PMC8168834 SCOPUS ID: 2-s2.0-85103656481 03/30/2021
The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill.

(Knight JM, Costanzo ES, Singh S, Yin Z, Szabo A, Pawar DS, Hillard CJ, Rizzo JD, D'Souza A, Pasquini M, Coe CL, Irwin MR, Raison CL, Drobyski WR.) Transl Psychiatry. 2021 01 18;11(1):58 PMID: 33462203 PMCID: PMC7812704 SCOPUS ID: 2-s2.0-85100097244 01/20/2021
Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT.

(Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE.) Blood Adv. 2021 01 12;5(1):66-70 PMID: 33570634 PMCID: PMC7805319 SCOPUS ID: 2-s2.0-85099204908 02/12/2021
Impact of Conditioning Intensity and Genomics on Relapse After Allogeneic Transplantation for Patients With Myelodysplastic Syndrome.

(Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Warlick ED, Pasquini MC, Scott BL, Horwitz ME, Deeg HJ, Hourigan CS.) JCO Precis Oncol. 2021;5 PMID: 34036237 PMCID: PMC8140814 05/27/2021
Pre-HCT mosaicism increases relapse risk and lowers survival in acute lymphoblastic leukemia patients post-unrelated HCT

(Wang Y, Zhou W, Wang J, Karaesmen E, Tang H, McCarthy PL, Pasquini MC, Wang Y, McReynolds LJ, Katki HA, Machiela MJ, Yeager M, Pooler L, Sheng X, Haiman CA, Van Den Berg D, Spellman SR, Wang T, Kuxhausen M, Chanock SJ, Lee SJ, Clay-Gilmour AI, Hahn TE, Gadalla SM, Sucheston-Campbell LE.) Blood Advances. 12 January 2021;5(1):66-70 SCOPUS ID: 2-s2.0-85099204908 01/12/2021
Corrigendum to ‘Ixazomib for chronic Graft-Versus-Host Disease prophylaxis following allogeneic hematopoietic cell transplantation’ [Biology of Blood and Marrow Transplantation 26/10 (2020) 1876-1885] (Biology of Blood and Marrow Transplantation (2020) 26/10(1876-1885) (S1083879120304146), (10.1016/j.bbmt.2020.07.005))

(Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, Fenske TS, Jerkins JH, Rizzo JD, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M.) Transplantation and Cellular Therapy. 2021 SCOPUS ID: 2-s2.0-85101258094 01/01/2021